Griffith University’s Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections. Human trials are set to begin as early as next year.
Strep A (Streptococcus pyogenes) is a major cause of infection-related deaths, leading to over 500,000 fatalities annually. Developing countries, Indigenous populations, and vulnerable groups face the greatest risks. A potential vaccine, developed by Professor Michael Good's team at Griffith University, is undergoing human trials and shows promise in fighting multiple Strep A strains.
As Streptococcus A cases continue to be prevalent in Queensland and internationally, a new nasal vaccine could provide long-term protection from the deadly bacteria.
Griffith University researchers have unlocked one of the secrets as to why some forms of Strep A are associated with severe invasive infection.
Griffith University’s Institute for Glycomics has been awarded $2.66 million in Ideas Grant funding from the National Health and Medical...
Strep A, which can lead to serious illness and death if untreated, should be recognised as a Neglected Tropical Disease...
Development of a vaccine that can treat the bacteria which causes Scarlet Fever and can lead to rheumatic fever, has the potential to save the lives of many Indigenous Australians and other lives worldwide.
